Standard BioTools (LAB) Announces Third Quarter 2025 Financial Earnings Results

Standard BioTools Inc. (LAB) today announced its financial results for the most recent quarter, revealing a mixed performance. The company reported a quarterly revenue of $19.55 million, surpassing analysts’ expectations by $1.55 million. However, Standard BioTools fell short on earnings per share, posting a loss of $0.08, which missed the estimate by $0.04.

Key Highlights:

• Total combined revenue for Q3 2025 was $46.2 million, with revenue from continuing operations at $19.6 million.
• The company implemented a restructuring plan expected to yield over $40 million in annualized cost savings, aiming for positive adjusted EBITDA by 2026.
• As of September 30, 2025, Standard BioTools had $217 million in cash and cash equivalents, with an expected $550 million from a transaction with Illumina in the first half of 2026 to support growth.
• The company reported a net loss of $31.7 million for Q3 2025, compared to a net loss of $21.9 million in Q3 2024.

Standard BioTools Inc. reported its financial results for the third quarter of 2025, highlighting a total combined revenue of $46.2 million, with $19.6 million coming from continuing operations. The company is undergoing a restructuring plan aimed at achieving over $40 million in annualized cost savings, which is expected to help them reach positive adjusted EBITDA by 2026. CEO Michael Egholm emphasized the company’s focus on simplifying operations and increasing productivity, stating, “The third quarter marked another period of solid execution as we sharpen our focus and position Standard BioTools for the next stage.”

The restructuring plan includes a reduction of approximately 20% of the global workforce and aims to enhance operational efficiency. CFO Alex Kim noted the importance of these decisions in maintaining a lean organization, stating, “Given the current operating environment, these decisions were important to keep our organization lean, focused and positioned to emerge stronger tomorrow than we are today.” The company continues to expect combined revenue for fiscal year 2025 to be in the range of $165 million to $175 million, with revenue from continuing operations projected between $78 million and $83 million.

Standard BioTools Inc. (LAB) has experienced a tumultuous ride in the stock market, with its price declining by 6.06% over the past week and a staggering 37.69% drop over the last year. Despite a modest uptick of 3.33% in the last six months, the overall trend remains concerning for investors. The company’s price-to-earnings ratio stands at a negative 3.72, indicating significant challenges in profitability, as reflected by a net profit margin of -87.6%. Furthermore, the return on invested capital is also in the red at -29.5%, raising questions about the efficiency of its capital allocation. On a brighter note, Standard BioTools has shown a robust revenue growth rate of 20.94% over the past two years, suggesting potential for recovery if the company can stabilize its operations and improve its financial health. However, the lack of positive free cash flow and the absence of a two-year compound annual growth rate for earnings per share highlight the need for strategic changes. Investors will be closely watching how the company navigates these challenges in the coming quarters.

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.